Acamprosate for ALS with C9orf72 gene change
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests a medication called acamprosate to see if it can slow down ALS in people who have a specific genetic change (C9orf72). If you have this gene change and ALS, this study might offer a new treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have ALS (any type) and a confirmed C9orf72 gene change.
- You have had symptoms for less than 2 years, or your disease is progressing slowly enough to finish the study.
- You can swallow tablets whole (no feeding tube needed for medication).
- You are not dependent on daytime breathing support (like a ventilator or CPAP/BiPAP).
- You are not pregnant, breastfeeding, or planning to become pregnant or father a child during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a supplement called acetyl-L-carnitine (ALCAR) to see if it can slow the progression of ALS. It is for people in the early stages of the disease who are already taking riluzole and have good lung and muscle function.
This trial tests whether adding two supplements (EH-301 and N-acetylcysteine) to the standard ALS medicine Riluzole can help slow the disease. It is for people diagnosed with ALS within the last 18 months who still have good breathing and daily function.
This trial tests whether a medicine called cyclophosphamide can slow the progression of ALS. It's given to people who have had symptoms for less than 2 years and still have good breathing, to see if calming the immune system can help protect nerve cells.
This trial tests a new treatment aimed at restoring the function of a gene called UNC13A in people with ALS. It involves multiple clinic visits, MRI scans, and spinal taps to see if the treatment is safe and may slow the disease.
This trial tests a personalized treatment designed for one patient with ALS (Lou Gehrig's disease) caused by a specific genetic change. The therapy aims to target the genetic cause, potentially slowing the disease, and this study will help learn if it's safe and beneficial.
This trial tests RAPA-501, a treatment made using your own immune cells, to slow progression of ALS. It may help by changing how your immune system responds in ALS.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.